Revagenix
Revagenix engineers precision therapies for serious chronic disease.
Series B+ ·
Amount not disclosed in a source on record.
Funding history ↓Signals
Website registeredMar 11, 2019 (7 years old)
About Revagenix
Our lead program, Rev-56, is an inhaled therapy entering Phase 1 for non-CF bronchiectasis.
Funding rounds
- Series B+ · amount undisclosedSource: fundraisingfox.com
- Website created
Founders and team
- RCRyan Cirz Co-founder & CEOsource: revagenix.com
- AMAndrew McCandlish Co-founder & COOsource: revagenix.com
Companies like Revagenix
AActio Biosciences$66M Series B+ · Jun 2025
CCelea Therapeutics$180M Series A · Jul 2026
PPulmocide$52M Series B+ · Dec 2022
KKinaset Therapeutics$103M Series B+ · Jan 2026
SStar Therapeutics$200M Series B+ · Oct 2026
MMatchpoint Therapeutics$150M Series B+ · Oct 2026
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/revagenix (get a free API key).